Bridge Biotherapeutics
Latest round
- Series B
Last raised
- Sep 2017
Total raised
- $25M
Investors
- 12
About Bridge Biotherapeutics
Based in Seongnam-si, South Korea, Bridge Biotherapeutics, Inc. is an NRDO (No Research Development Only) biopharmaceuticals company that focuses on the development of new drugs and drug platforms for respiratory, inflammation, and oncology diseases. In 2015, Bridge Biotherapeutics, Inc. acquired an in-licensing agreement for BBT-401, a drug candidate for ulcerative colitis. In 2016, Bridge Biotherapeutics, Inc. established its subsidiary in the US. In 2019, Bridge Biotherapeutics, Inc. was listed on the KOSDAQ. The current CEO of the company is James Jungkue Lee. Bridge Biotherapeutics, Inc. develops several pipelines for respiratory, inflammation, and oncology diseases. Some of the main pipelines include BBT-877, autotaxin inhibitor, BBT-401, Pelino-1 inhibitor, and BBT-176, EGFR Tyrosine Kinase inhibitor. All of the three pipelines have passed pre-clinical study.
Who invested in Bridge Biotherapeutics
12 investors across 2 rounds
See all investors in Bridge Biotherapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Bridge Biotherapeutics
Who invested in Bridge Biotherapeutics?
Bridge Biotherapeutics has 12 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Bridge Biotherapeutics raised?
Bridge Biotherapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Bridge Biotherapeutics last raise money?
Bridge Biotherapeutics's most recent round on record is a Series B, in Sep 2017.
What does Bridge Biotherapeutics do?
Based in Seongnam-si, South Korea, Bridge Biotherapeutics, Inc.
Where is Bridge Biotherapeutics headquartered?
Bridge Biotherapeutics is headquartered in Seongnam, South Korea.
Which VCs invest in companies like Bridge Biotherapeutics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Bridge Biotherapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Bridge Biotherapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.